Clinical Trial Update: Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.

View source ↗

Summary

A post-marketing surveillance study assessed the tolerability of Rebif's new formulation in relapsing multiple sclerosis patients in Australia. The study is com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Rebif (interferon beta-1a)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Multiple Sclerosis | Status: COMPLETED